Brandon Capital

📣 Brandon Capital portfolio company, George Medicines, which is finalising its FDA New Drug Application, submission is in the news. ⬇️GMRx2, a groundbreaking three-in-one polypill candidate for hypertension, demonstrated blood pressure control in an incredible 70% of patients. 🌏 Research underpinning the development of GMRx2 originated from Brandon BioCatalyst member, The George Institute for Global Health. 💰Brandon Capital is proud to invest alongside The George Institute for Global Health, Federation Private Equity and Bupa to bring this groundbreaking therapy to life. Coverage of what the George Medicines Phase 3 clinical trial results mean for people living with hypertension are in the comments if you'd like to read more. #HypertensionInnovation #GlobalHealth #ClinicalTrialsSuccess #Polypill #georgemedicines

🚨 One week to go! Expressions of Interest for CUREator+, a national biomedical and digital health technology incubator program, close soon. 📅 Submit your EOI by 12pm AEDT, Wednesday 4 December. With up to $5 million in non-dilutive funding available, CUREator+ supports the preclinical, clinical, and commercial development of: 🔹 Medical and connected devices 🔹 Digital health technologies 🔹 Therapeutics Start grant application 👉🏿 https://lnkd.in/g7FDwCJm Learn more about the program 👉🏼 https://lnkd.in/g2x5_Cbs CUREator+ is delivered in partnership with ANDHealth with funding from the MRFF BioMedTech Incubator (BMTI) program.

👏👏👏 Exciting news from our portfolio company, Pathios Therapeutics! We’re thrilled to see them reaching a significant clinical milestone by dosing the first patient in their Phase 1/2 trial for PTT-4256. A first-in-class GPR65 small molecule inhibitor, PTT-4256 represents a potentially groundbreaking approach to overcoming immune suppression in the acidic tumour microenvironment. The RAISIC-1 trial, being conducted in Australia, will evaluate the safety, tolerability, and early efficacy of PTT-4256 across advanced solid tumours. 📖 Read the full press release in their release below #FirstPatient #GPR65 #ImmunoOncology

🏆🏆🏆Congratulations to all the finalists and award winners recognised at the 2024 European Lifestars Awards - Celebrating Life Science Leaders. We were thrilled to see Brandon Capital's portfolio companies CatalYm GmbH, Myricx Bio, and Pheon Therapeutics achievements acknowledged and bravo to our UK-based partner, Dr Jonathan Tobin, for leading these investments. These companies are pioneering new oncology treatments, and we are honoured to support their innovations. #OncologyInnovation #LifeSciencesAwards #BiotechBreakthroughs #CancerResearch

🌟 Aravax: Advancing Peanut Allergy Treatments with BTF Support Thank you to the Department of Industry, Science and Resources for showcasing the Aravax journey. 🥜Established in 2015 to develop PVX108, a potential disease-modifying treatment for peanut allergy, Aravax received a $12.9 million investment from the Biomedical Translation Fund (BTF). 🥜The pivotal funding enabled the completion of early-stage clinical trials in Australia, generating a robust dataset that paved the way for international Phase 2 clinical trials, culminating in US$42 million in Series B funding. "We are at the forefront globally in developing the next generation of immunotherapy. Without the early support from the BTF, we wouldn’t be where we are today. It was instrumental in producing the data needed to attract both local and international investment." Dr Pascal Hickey Congratulations also to Brandon Capital Partner, Dr Chris Smith, who leads our investment in Aravax. #LifeSciences #Biotech #Innovation #PeanutAllergy #VentureCapital #HighSkilledJobs

📢 Some of our team are in London for the Jefferies Healthcare conference, where they attended the Welcome to London Life Sciences Week (LLSW) reception hosted by the BioIndustry Association (BIA) last night. Please contact them if you'd like to learn more about Brandon Capital and our portfolio companies. 💠Chris Nave - Certa Therapeutics, PolyActiva, Pathios Therapeutics 💠Chris Smith - Aravax, ENA Respiratory, Denteric Pty Ltd 💠Jonathan Tobin - CatalYm GmbH, Myricx Bio, NRG Therapeutics, Pheon Therapeutics #JefferiesHealthcareConference #LLSW2024 #Biotech #HealthcareInnovation

❓Did you know biotech startups that join incubator programs tend to perform better than those that don't due to the resources, mentorship, and networking opportunities they receive? Applications for CUREator + Round Two are open, and here are some excellent resources to help prepare your Expression of Interest, which closes on 4 December. 🌐 Learn more about the program https://lnkd.in/g45fjDA7 or https://lnkd.in/gXn92zma 📹 Request a copy of the Information Session webinar https://lnkd.in/gaukAsjM 📧 Book a meeting by emailing CUREator info@cureator.com.au or ANDHealth cureatorplus@andhealth.com.au 🎟️Attend CUREator at Jumar this Thursday https://lnkd.in/gJnsjdnX CUREator+, a partnership between Brandon BioCatalyst and ANDHealth, is supported by the Medical Research Future Fund. Reference for opening claim 👉🏾https://lnkd.in/gMXT9KyW #biotech #growth #innovation #investment

🌟Over the last four months, the Brandon Capital team had the absolute privilege of working with some of Victoria's brightest emerging biotech leaders through the Victorian Biotech Innovators Program. Here are some of our favourite memories: 👩🏻🔬The impact of guest speakers Dr Andrew Nash, Dr Julie Cherrington, Dr Nick Wilson, Dr Jonathan Tobin, and Professor Ian Charles OBE FLS O.B.E who were so generous with their commercialisation and innovation insights. 🔬Learning about projects spanning genetic modelling to understand better neurological disorders, synthetic antimicrobial solutions, bioengineered skin for burn treatment, and Australia's first stem cell bank for pets, to name just a few. 🥲The times you could have heard a pin drop, the thought-provoking questions and the infectious energy and optimism we felt during workshops and networking. Congratulations to everyone involved! We’re excited to follow your journeys. A program such as this demonstrates biotech's vast potential and impact, which wouldn’t have been possible without the support of the Victoria State Government (Victorian Government) Department of Jobs, Skills, Industry and Regions. #BrandonCapital #VictorianBiotech #Innovation #ResearchTranslation #BiotechLeadership

Looking for actionable insights on securing funding for your biotech? Whether you're starting out or scaling up, join a seminar hosted by the CUREator team where Brandon Capital Partners and CUREator alums will share their practical tips and firsthand experiences. Dr Patricia Rueda will lead discussions with Brandon Capital Partners, Dr Jonathan Tobin, and Dr Chris Smith, who will share what they look for in new investments. Plus, hear from CUREator alums—Denteric Pty Ltd, Alkira Bio, Proxima Bio, and RAGE Biotech—who will share what they've learned on their funding journeys. 📅Thursday, 14 November 2024 🕰️ 10 am to 11.30 am, followed by networking 📍 Jumar Bioincubator, 655 Elizabeth Street, Melbourne. 👇🏽 Register to secure your spot, and we'd appreciate you tagging in someone who might be interested. https://lnkd.in/gJnsjdnX

👏 👏 👏 to the Vaxxas team on announcing The National Institutes of Health's licensing of your DS2 vaccine antigen candidate for use in RSV prophylactic vaccines. 🌍 Why It Matters: Respiratory Syncytial Virus (RSV) leads to an estimated 33 million acute respiratory infections annually. 💡 Innovative Delivery: Vaxxas' cutting-edge needle-free technology utilises a patch with thousands of microprojections to deliver the vaccine directly to immune cells, simplifying administration and eliminating the need for refrigeration. 🚀 Next Steps: After completing pre-clinical development, Vaxxas is set to progress to Phase I clinical trials. Vaxxas CEO David Hoey, "Published preclinical results show the potential immunogenic advantages of this antigen candidate as the basis for an RSV vaccine that will provide robust and durable protection. "These potential advantages, coupled with the potential of the Vaxxas needle-free technology to eliminate the need for refrigerated distribution and enable self-administration, could offer a vaccine that significantly impacts how we protect populations against this serious respiratory infection in the future." We're proud to support Vaxxas as they drive pioneering solutions in public health. Read more in @AuManufacturing news and media 👇🏿 https://lnkd.in/gKU-X7Sc #BrandonCapital #Biotech #RSVVaccine #InnovationInHealth #ClinicalTrials